Skip to main content
Erschienen in: BMC Urology 1/2022

Open Access 01.12.2022 | Research

Risk factors for kidney stone disease recurrence: a comprehensive meta-analysis

verfasst von: Kai Wang, Jing Ge, Wenlong Han, Dong Wang, Yinjuan Zhao, Yanhao Shen, Jiexun Chen, Dongming Chen, Jing Wu, Ning Shen, Shuai Zhu, Bin Xue, Xianlin Xu

Erschienen in: BMC Urology | Ausgabe 1/2022

Abstract

Background

Kidney stone disease (KSD) is a common illness that causes an economic burden globally. It is easy for patients to relapse once they have suffered from this disease. The reported recurrence rate of KSD ranged from 6.1% to 66.9%. We performed this meta-analysis to identify various potential risk factors for the recurrence of KSD.

Methods

The PubMed, Embase and Web of Science databases were searched using suitable keywords from inception to Mar 2022. A total of 2,663 records were collected initially. After screening the literature according to the inclusion and exclusion criteria, 53 articles (40 retrospective studies; 13 prospective studies) including 488,130 patients were enrolled. The study protocol was registered with PROSPERO (No. CRD42020171771).

Results

The pooled results indicated that 12 risk factors including younger age (n = 18), higher BMI (n = 16), family history of kidney stones (n = 12), personal history of kidney stones (n = 11), hypertension (n = 5), uric acid stone (n = 4), race of Caucasian (n = 3), suspected kidney stone episode before the first confirmed stone episode (n = 3), surgery (n = 3), any concurrent asymptomatic (nonobstructing) stone (n = 2), pelvic or lower pole kidney stone (n = 2), and 24 h urine test completion (n = 2) were identified to be associated with KSD recurrence. In the subgroup analysis, patients with higher BMI (OR = 1.062), personal history of nephrolithiasis (OR = 1.402), or surgery (OR = 3.178) had a higher risk of radiographic KSD recurrence.

Conclusions

We identified 12 risk factors related to the recurrence of KSD. The results of this analysis could serve to construct recurrence prediction models. It could also supply a basis for preventing the recurrence of KSD.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12894-022-01017-4.
Kai Wang, Jing Ge, Wenlong Han and Dong Wang contributed equally to this work

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
KSD
Kidney stone disease
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
MOOSE
Meta-analysis of observational studies in epidemiology
OR
Odds ratio
RR
Relative risk
HR
Hazard ratio
CI
Confidence interval
BMI
Body mass index
NOS
Newcastle–Ottawa Quality Assessment Scale
ESWL
Extracorporeal shock wave lithotripsy
SS
Supersaturation
DG
Delta Gibb’s free energy
GFR
Glomerular filtration rate
SC
Single center
MC
Multi-center
NA
Not available
CS
Calcium stone
COS
Calcium oxalate stone
MAPS
Magnesium-ammonium calcium phosphate stone
y
Year
m
Month

Background

Kidney stone disease (KSD) is a common issue with a high health care burden that affects the quality of life among the global population. The incidence rate of nephrolithiasis increases annually, estimated to be 14% in England and 10.1% in the United States [1, 2]. Its etiology is multifactorial and includes age, sex, geography, climate, race, dietary, genetic factors and so on [3]. Approximately half of the patients with nephrolithiasis will undergo a second episode of renal colic within 10 years [4]. More than 10% of patients could experience more relapses [5]. The probability of symptomatic stone recurrence in children reached 50% within 3 years [6]. Additionally, the recurrence rate of urinary calculi in patients with specific stone mineral compositions and morphologies can even be up to 82.4% [7].
The recurrence of KSD varies greatly among different patients. Some patients have nephrolithiasis only once, while others have frequent recurrences. Although preventive measures such as diet and drugs have been implemented and have achieved significant results, the effectiveness of these interventions is still limited [8, 9]. Identifying risk factors for relapse of KSD can help clinicians develop better preventive intervention plans for patients.
Existing studies have only summarized limited risk factors for KSD recurrence [10, 11]. Nevertheless, KSD recurrence is likely associated with several different risk factors. When multiple risk factors are present, systematic evaluation is positive for individualized treatment. In addition, the relationships reported in the existing studies between some known risk factors and kidney stone recurrence are inconsistent [12]. Thus, the aim of this meta-analysis was to comprehensively explore various potential risk factors for the recurrence of KSD.

Methods

Search strategy

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Meta-analysis of observational studies in epidemiology (MOOSE) guidelines were utilized when this meta-analysis was conducted [13]. The PubMed, Embase and Web of Science databases were searched to identify the studies that determined the association between various risk factors and recurrence of KSD. The keywords used were ‘Nephrolithiasis’ OR ‘Nephrolith’ OR ‘Kidney Calculus’ OR ‘Kidney Stones’ OR ‘Kidney Stone’ OR ‘Renal Calculi’ (all fields) AND ‘Relapse’ OR ‘Relapses’ OR ‘Recurrences’ OR ‘Recrudescence’ OR ‘Recrudescences’ (all fields) AND ‘risk factor’ OR ‘association’ OR ‘relative risk’ OR ‘odds ratio’ OR ‘Populations at Risk’ (all fields). The complete Boolean formula regarding the keywords and search hits is shown in Additional file 1: Table S1. Two investigators (KW and JG) independently performed the retrieval on Mar 11, 2022. The references of the identified papers were also screened to determine further potential studies. This study protocol was registered with PROSPERO (No. CRD42020171771).

Selection criteria

Eligible studies were screened according to the following criteria: (1) any prospective or retrospective study reported the risk factors for recurrence of KSD; (2) sufficient data to estimate the odds ratio (OR), relative risk (RR), or hazard ratio (HR) and their 95% confidence intervals (CIs) reported according to the risk factors; and (3) only complete or the latest studies were included in several studies reported the same risk factors in the same cohort. The recurrence of KSD was defined as the symptomatic, radiographic appearance, or repeated interventions of stones. Reviews, case reports, nonhuman trials, letters, conference abstracts and comments were excluded. Cross-sectional studies were excluded. Studies whose control groups contained healthy subjects or sample sizes were < 40 or lacked key data were also excluded. If only the Kaplan–Meier curves of risk factors for recurrence of KSD were available, we extracted the HR and 95% CI data. The titles and abstracts of all literature were first independently screened by two authors. Further evaluation was conducted by browsing the full texts. Any disagreement was eventually resolved.

Data extraction and quality assessment

DMC and YHS independently extracted the data required from all eligible studies. JW and DW assessed the quality of each study according to the Newcastle–Ottawa Quality Assessment Scale (NOS) as described in our previous work [14, 15]. Information on the first author’s surname, publication year, population characteristics, sample size, follow-up time, the recurrence rate of KSD, and risk factors for recurrence of KSD.

Statistical analysis

Any RR and HR with similar values were merged into OR. Pooled ORs and their 95% CIs were used to describe the relationship between various risk factors and recurrence of KSD. A minimum of 2 studies for a risk factor were analyzed. Heterogeneity was assessed by Cochran’s Q test and Higgins’ I-squared statistics. When I2 > 50% and/or P < 0.1, a random-effects model was used. Otherwise, a fixed-effects model was applied. Publication bias was detected with an asymmetrical funnel plot and cross-checked by Begg’s and Egger’s tests. The trim-and-fill method was used if publication bias existed. Subgroup analysis was conducted based on the definition of radiographic KSD relapse to reduce the impact of heterogeneity. All data were analyzed by STATA software version 12.0 (Stata Corporation, College Station, TX, USA). P < 0.05 was considered statistically significant.

Results

Study characteristics

First, a total of 2,663 records (PubMed: 1,561; Embase: 207; Web of Science: 940) were collected. A total of 399 articles were further evaluated carefully after deduplication and reviewing the title and abstracts. A total of 344 studies were further excluded, which lacked important data. 2 cross-sectional studies were also excluded. Eventually, 53 articles, including 488,130 patients, were enrolled in this analysis [6, 1667] (Fig. 1). These patients were from the USA (94.90%), Japan (2.80%), China (0.57%), Italy (0.55%), Korea (0.52%), Egypt (0.16%), Germany (0.13%), Israel (0.09%), Turkey (0.08%), Spain (0.05%), Canada (0.04%), France (0.04%), Iceland (0.04%), Belgium (0.02%), and Sweden (0.01%).
The characteristics of these enrolled studies are shown in Table 1. Approximately 17.4% of patients enrolled in this study experienced the recurrence of KSD. The patients in four studies [26, 35, 42, 43] were from the same research institutions. However, the collection time and the risk factors they reported were not exactly the same. Thus, these four studies were still included in this meta-analysis. Additionally, two other researches [18, 28] may have the same cohort. After comparison, we screened the possible duplicate data and retained which item had more participants. There were 40 retrospective studies and 13 prospective studies enrolled in our analysis. Populations from Caucasian, Asian and mixed races were reported in 20, 14, and 19 studies, respectively.
Table 1
Main characteristics of all studies included in this analysis
Study
Nation
Research type
Time data collected
Sampling frame
Follow-up time
Stone types
Race
Age
Sample size
Man (%)
Recurrence rate (%)
Ratio
Song et al. [16]
USA
Retrospective
2007–2013
SC
Median 64 m
NA
Mixed
Mean 57.6
14,854
93.81
57.60
HR
Ito et al. [17]
Japan
Retrospective
2012–2019
SC
Median 31 m
Mixed
Asian
Mean 60.0
664
63.00
20.33
HR
Iremashvili et al. [18]
USA
Retrospective
2009–2017
SC
Mean 4.3 y
NA
Mixed
Mean 54.9
1,970
51.62
20.96
HR
Samson et al. [19]
USA
Retrospective
2007–2017
SC
3 y
NA
Mixed
Mean 46.0
434,055
57.69
14.50
OR
Prasanchaimontri and Monga [20]
USA
Retrospective
2002–2012
SC
Median 10 y
Mixed
Mixed
NA
1,617
62.71
23.07
OR
Nevo et al. [21]
Israel
Retrospective
2010–2015
SC
Median 38 m
Mixed
Caucasian
Median 53
457
69.20
24.29
HR
Islam et al. [22]
USA
Retrospective
2008–2018
SC
10 y
NA
Mixed
Mean 57.6
69
44.93
23.19
OR
Ingvarsdottir et al. [23]
Iceland
Retrospective
1985–2013
SC
Median 12 y
Mixed
Caucasian
Median 15
190
41.05
35.79
HR
Castiglione et al. [24]
USA
Prospective
2009
SC
5 y
NA
Mixed
Mean 48.2
375
54.80
21.07
OR
Vaughan et al. [25]
USA
Retrospective
1984–2012
SC
NA
NA
Mixed
Mean 43.9
3,364
60.79
26.22
HR
Kang et al. [26]
Korea
Retrospective
1994–2017
SC
15 years
NA
Asian
Mean 49.1
680
60.15
41.18
HR
Iremashvili et al. [27]
USA
Retrospective
2009–2016
SC
Median 4.8 y
NA
Mixed
Mean 53.6
498
52.21
17.67
HR
Iremashvili et al. [28]
USA
Retrospective
2009–2017
SC
Mean 4.1 y
NA
Mixed
Mean 54.8
1,496
52.07
24.53
HR
Ruysscher et al. [29]
Belgium
Retrospective
1998–2016
SC
NA
NA
Caucasian
Median 3.9
97
73.20
34.02
OR
Costa et al. [30]
USA
Prospective
2009–2013
SC
5 y
Mixed
Mixed
Mean 49.6
175
53.14
66.86
OR
Yamashita et al. [31]
Japan
Retrospective
2011–2015
SC
NA
NA
Asian
Median 59
300
69.33
49.33
OR
Wang et al. [32]
China
Retrospective
2015
SC
NA
COS
Asian
mean 50.6
72
75.00
50.00
OR
Ozgor et al. [33]
Turkey
Retrospective
2011–2013
SC
Mean 33.3 m
Mixed
Caucasian
Mean 47.33
202
53.11
22.28
OR
Ferraro et al. [34]
Italy
Prospective
1993–1994
SC
5 y
COS
Caucasian
Mean 45.3
103
NA
33.98
HR
Tasian et al. [6]
USA
Retrospective
2008–2014
SC
3 y
Mixed
Caucasian
Median 14.8
285
45.61
23.86
HR
Kang et al. [35]
Korea
Retrospective
1994–2015
SC
NA
Mixed
Asian
Mean 44.9
624
63.58
37.66
HR
Shih et al. [36]
China
Retrospective
2000–2002
SC
Mean 8.9 y
NA
Asian
Mean 27.48
1,474
0.00
16.62
HR
Guerra et al. [37]
Italian
Retrospective
1986–2013
SC
NA
CS
Caucasian
NA
2,080
61.01
6.11
OR
El-Assmy et al. [38]
Egypt
Retrospective
1998–2011
SC
10 y
Mixed
Caucasian
Mean 41.3
784
73.09
25.26
HR
Bos et al. [39]
Canada
Prospective
2009–2010
SC
5 y
NA
Caucasian
Mean 54.5
110
63.64
25.45
HR
Liu et al. [40]
China
Retrospective
1999–2010
SC
NA
NA
Asian
Mean 52.8
1,259
85.94
13.26
HR
Rule et al. [41]
USA
Retrospective
1984–2003
SC
NA
Mixed
Mixed
Mean 41.7
2,239
62.48
31.58
HR
Kang et al. [42]
Korea
Retrospective
1994–2010
SC
Median 35 m
Mixed
Asian
NA
240
NA
23.33
HR
Kang et al. [43]
Korea
Retrospective
2007–2011
SC
NA
Mixed
Asian
Mean 60.4
342
48.25
16.96
HR
Kruck et al. [44]
Germany
Retrospective
2001–2007
SC
NA
Mixed
Caucasian
Mean 51.5
482
66.00
NA
OR
Kohjimoto et al. [45]
Japan
Retrospective
2005
MC
7 y
Mixed
Asian
Mean 52.5
11,555
73.86
57.14
OR
Sorensen et al. [46]
USA
Retrospective
2001–2010
SC
NA
NA
Caucasian
Mean 55
40
32.50
22.50
OR
Pieras et al. [47]
Spain
Retrospective
2003–2007
SC
Mean 60 m
Mixed
Caucasian
Mean 44
248
69.76
48.79
HR
Ha et al. [48]
Korea
Retrospective
1994–2008
SC
NA
CS
Asian
NA
247
NA
39.68
HR
DeFoor et al. [49]
USA
Retrospective
1999–2006
SC
NA
Mixed
Mixed
Mean 12.7
139
52.52
36.69
OR
Kim et al. [50]
Korea
Retrospective
1994–2007
SC
Median 49 m
CS
Asian
mean 44.3
266
65.20
41.73
HR
Lee et al. [51]
Korea
Retrospective
1996–2006
SC
Median 54 m
Mixed
Asian
Mean 42.9
163
66.76
36.20
HR
Krambeck et al. [52]
USA
Retrospective
1983–1984
SC
 > 5 y
Mixed
Mixed
NA
375
64.80
49.60
OR
Unal et al. [53]
Turkey
Retrospective
NA
SC
NA
NA
Caucasian
Mean 35
173
50.87
28.32
HR
Daudon et al. [54]
France
Retrospective
1984–2000
SC
3 y
COS
Caucasian
Mean 30.4
181
70.17
39.78
HR
Abe et al. [55]
Japan
Retrospective
1987–2000
SC
5 y
Mixed
Asian
Mean 45.7
11,39
72.10
28.62
OR
Parks et al. [56]
USA
Prospective
1970–2003
SC
30 y
ICN
Mixed
Mean 33.0
1,201
70.86
NA
HR
Mardis et al. [57]
USA
Prospective
1995–1996
SC
7 y
Mixed
Mixed
NA
203
70.44
29.06
HR
Afshar et al. [58]
Canada
Retrospective
1990–2002
SC
Mean 46 m
Mixed
Caucasian
Mean 7
83
46.99
31.33
OR
Siener et al. [59]
Germany
Prospective
NA
SC
2 y
COS
Caucasian
Mean 51.7
134
67.16
42.54
OR
Chen et al. [60]
USA
Retrospective
1973–1996
SC
5 y
NA
Mixed
Mean 37
62
87.10
30.65
RR
Borghi et al. [61]
Italy
Prospective
1993–1994
SC
5 y
COS
Caucasian
Mean 45.1
120
100.00
43.33
RR
Jendle-Bengten et al. [62]
Sweden
Retrospective
NA
SC
Mean 5.6 y
COS
Caucasian
Mean 50
52
73.08
51.92
HR
Trinchieri et al. [63]
Italy
Prospective
1980–1990
SC
Mean 19.3 y
Mixed
Caucasian
Mean 44.3
195
50.26
26.67
HR
Ettinger et al. [64]
USA
Prospective
NA
SC
3 y
COS
Mixed
Mean 48.0
64
78.13
39.06
RR
Hiatt et al. [65]
USA
Prospective
1984–1985
MC
4.5 y
COS
Mixed
Mean 43.0
99
78.79
14.14
HR
Gambaro et al. [66]
Italy
Prospective
1984–1986
SC
9 y
NA
Caucasian
Median 34
190
65.79
57.89
OR
Streem [67]
USA
Prospective
1983
SC
Mean 41.7 m
MAPS
Mixed
Mean 53.2
44
20.45
27.27
OR
SC, single center; MC, multi-center; NA, not available; OR, odds risk; RR, relative risk; HR, hazard risk; CS, calcium stone; COS, calcium oxalate stone; MAPS, magnesium-ammonium calcium phosphate stone; y, year; m, month

Quality assessment

All the studies included in this meta-analysis were assessed according to the NOS. The average quality score of the studies was 7.8 (ranging from 5 to 9). All the studies including 48 high-quality and 5 moderate-quality studies were performed using an improved methodology. For further analysis, all the studies mentioned above were enrolled.

Demographic risk factors

Eleven variables, including age [6, 1618, 2022, 2527, 31, 32, 36, 41, 42, 47, 48, 50], body mass index (BMI) [6, 17, 18, 2023, 25, 26, 29, 32, 35, 42, 45, 46, 51], sex [6, 16, 17, 20, 21, 23, 2528, 31, 32, 35, 4042, 45, 46, 48, 50, 59, 63, 66], race [18, 27, 41], pregnant or childbirth [25, 36], gout [16, 18, 40], diabetes [16, 18, 31, 40, 45], hypertension [16, 18, 31, 40, 45], hyperlipidemia [31, 40, 45], osteoporosis [16, 40], and urinary tract anomalies [59, 67] were available for data pooling (Table 2).
Table 2
The pooled relationship between various risk factors and relapse of kidney stone disease
Risk factors
No. of studies
No. of patients
OR (95% CI)
P value
Model
Heterogeneity
I2(%)
P
Demographic risk factors
Age
18
28,315
0.980 (0.966–0.995)
0.009#
Random
84.7
< 0.001§
BMI
16
22,087
1.045 (1.008–1.083)
0.016*
Random
62.4
< 0.001§
Sex
23
41,466
1.046 (0.945–1.157)
0.388
Random
65.8
< 0.001§
Race
3
4,707
1.338 (1.033–1.732)
0.027*
Fixed
0.0
0.982
Pregnant or childbirth
2
3,609
0.896 (0.228–3.525)
0.875
Random
96.8
< 0.001§
Gout
3
18,083
1.181 (0.745–1.871)
0.479
Random
79.4
0.008#
Diabetes
5
29,938
1.095 (0.959–1.251)
0.179
Random
56.3
0.058
Hypertension
5
29,938
1.126 (1.076–1.178)
 < 0.001§
Fixed
0.0
0.579
Hyperlipidemia
3
13,114
1.020 (0.670–1.553)
0.925
Random
74.4
0.020*
Osteoporosis
2
16,113
1.140 (0.743–1.749)
0.550
Random
52.5
0.147
Urinary tract anomalies
2
178
1.098 (0.274–4.405)
0.895
Random
65.8
0.087
Kidney stone-related risk factors
Family history of kidney stones
12
11,912
1.194 (1.078–1.323)
0.001#
Random
46.8
0.037*
Personal history of kidney stones
11
10,784
1.428 (1.230–1.658)
< 0.001§
Random
52.1
0.022*
Any gross hematuria with first symptomatic stone
2
2,737
1.068 (0.893–1.276)
0.473
Fixed
0.0
0.324
Suspected kidney stone episodea prior to first confirmed stone episode
3
6,101
1.815 (1.559–2.114)
< 0.001§
Fixed
0.0
0.802
Any concurrent asymptomatic (nonobstructing) stone
2
2,737
1.711 (1.464–1.999)
< 0.001§
Fixed
2.0
0.312
Uric acid stone
4
4,602
1.957 (1.414–2.707)
< 0.001§
Fixed
40.0
0.172
Calcium oxalate monohydrate
2
3,612
0.897 (0.785–1.025)
0.110
Fixed
0.0
0.331
Calcium phosphate stone
2
1,865
1.271 (0.592–2.731)
0.538
Fixed
37.2
0.207
Diameter of largest kidney stone
8
3,771
1.047 (0.995–1.101)
0.076
Random
74.4
< 0.001§
Multiple calculi
4
1,760
1.338 (0.965–1.855)
0.080
Random
80.3
0.002#
Bilateral nephrolithiasis
2
2,218
2.175 (0.860–5.500)
0.101
Random
82.2
0.018*
Pelvic or lower pole kidney stone
3
6,101
1.666 (1.264–2.195)
< 0.001§
Random
76.6
0.014*
Ureteral stone
2
1,387
0.888 (0.380–2.075)
0.785
Random
85.7
0.008#
Ureterovesical junction stone
3
6,101
0.845 (0.761–0.937)
0.001#
Fixed
0.0
0.439
Treatment method risk factors
Stone prevention medications
9
4,316
0.752 (0.548–1.033)
0.078
Random
76.0
< 0.001§
Potassium citrate
4
2,992
0.732 (0.345–1.554)
0.417
Random
87.7
< 0.001§
Surgery
3
8,23
2.161 (1.557–2.998)
< 0.001§
Fixed
0.0
0.457
ESWl
4
1,495
1.756 (0.606–5.086)
0.299
Random
93.9
< 0.001§
24-h urine and serum tests related risk factors
Baseline urine volume
6
1,789
0.934 (0.756–1.154)
0.528
Random
64.0
0.016*
Baseline urine calcium
8
2,552
1.001 (0.997–1.005)
0.531
Random
55.9
0.026*
Baseline low urine citrate
7
2,371
1.000 (0.998–1.002)
0.994
Random
55.6
0.035*
Baseline urine oxalate
7
2,371
0.999 (0.993–1.004)
0.675
Fixed
26.3
0.228
Baseline urine sodium
4
1,719
1.001 (0.999–1.002)
0.325
Fixed
0.0
0.563
Baseline urine uric acid
6
2,232
1.000 (0.999–1.001)
0.992
Random
51.1
0.069
Baseline urine magnesium
3
1,095
1.081 (0.777–1.503)
0.645
Fixed
0.0
0.780
Baseline urine phosphate
2
422
0.978 (0.315–3.038)
0.969
Random
89.4
0.002#
Baselin urine osmolality
2
855
1.257 (0.629–2.515)
0.517
Random
83.3
0.014*
CaOx SS (DG)
2
314
0.808 (0.611–1.068)
0.134
Fixed
0.0
0.972
Serum calcium
2
348
1.033 (0.787–1.356)
0.817
Fixed
0.0
0.790
GFR
3
1,094
1.017 (0.963–1.074)
0.539
Random
92.3
< 0.001§
24 h urine test completion
2
448,909
1.157 (1.128–1.186)
 < 0.001§
Fixed
0.0
0.519
BMI, body mass index; OR, odds ratio; CI, confidence intervals; ESWl, extracorporeal shock wave lithotripsy; SS, supersaturation; DG, delta Gibb’s free energy; GFR, glomerular filtration rate
*P < 0.05; #P < 0.01; §P < 0.001
The pooling data suggested that the patients with older age would have a lower risk for recurrence of KSD. Caucasian and the patients with higher BMI or hypertension would have a higher risk for recurrence of KSD (Additional file 2: Figure S1). Meanwhile, sex, pregnant or childbirth, gout, diabetes, hyperlipidemia, osteoporosis, or urinary tract anomalies might not be the risk factors for recurrence of KSD. No publication bias appeared.
Fourteen variables including family history of nephrolithiasis [18, 22, 25, 27, 35, 37, 41, 42, 48, 50, 54, 59], personal history of nephrolithiasis [18, 25, 27, 29, 38, 39, 41, 48, 51, 53, 55], any gross hematuria with first symptomatic stone [27, 41], suspected nephrolithiasis episode a prior to first confirmed stone episode [25, 27, 41], any concurrent asymptomatic (nonobstructing) stone [27, 41], uric acid stone [20, 27, 41, 47], calcium oxalate monohydrate stone [25, 47], calcium phosphate stone [20, 47], diameter of largest nephrolithiasis [17, 21, 32, 38, 44, 53, 55], multiple stones [42, 48, 55, 59], bilateral nephrolithiasis [18, 47], pelvic or lower pole nephrolithiasis [25, 27, 41], ureteral stone [47, 55], and ureterovesical junction stone [25, 27, 41] were available for data pooling (Table 2). Personal history of nephrolithiasis was defined as the nephrolithiasis history prior to the medical records investigated.
The pooling data suggested that the patients with family history of nephrolithiasis, personal history of nephrolithiasis, suspected nephrolithiasis episode a prior to first confirmed stone episode, any concurrent asymptomatic (nonobstructing) stone, pelvic or lower pole nephrolithiasis, or uric acid stone would have a higher risk for recurrence of KSD (Additional file 2: Figure S2). Additionally, patients with ureterovesical junction stone might have a lower risk in KSD recurrence. Meanwhile, any gross hematuria with first symptomatic stone, calcium oxalate monohydrate stone, calcium phosphate stone, diameter of largest nephrolithiasis, multiple stones, bilateral nephrolithiasis or ureteral stone might not be the risk factors for recurrence of KSD.
The P value of Egger’s test of the diameter of largest nephrolithiasis was 0.01. After being adjusted with the method of trim-and-fill, the pooled data was still not statistically significant (OR = 1.024, 95% CI = 0.963–1.089, P = 0.456). Thus, the pooled result for diameter of largest nephrolithiasis was reliable. No publication bias appeared in other analysis of risk factors.
Three variables containing stone prevention medications treatment, surgery treatment and extracorporeal shock wave lithotripsy (ESWL) were available for data pooling (Table 2).

Stone prevention medications

The pooling data from 7 articles [17, 20, 21, 40, 57, 62, 64] including 9 studies containing 4,316 patients suggested that being treated with stone prevention medications may not lower the risk of KSD recurrence (I2 = 76.0%, P < 0.001; OR = 0.752, 95% CI = 0.548–1.033, P = 0.078) (Table 2). No publication bias appeared.
Additionally, we pooled the data from 4 studies [20, 40, 62, 64] reporting the risk factor of potassium citrate. The results showed that treatment with potassium citrate may not lower the risk of KSD recurrence (I2 = 87.7%, P < 0.001; OR = 0.732, 95% CI = 0.345–1.554, P = 0.417) (Table 2). The publication bias did not exist.

Surgery versus conservative treatment

The pooling data from 3 studies [17, 29, 60] containing 823 patients suggested that the patients need to be treated with surgery would have a higher risk for recurrence of KSD (I2 = 0.0%, P = 0.457; OR = 2.161, 95% CI = 1.557–2.998, P < 0.001) (Additional file 2: Figure S3A). No publication bias appeared.

ESWL versus other treatment

The pooling data from 4 studies [33, 38, 52, 59] containing 1,495 patients suggested that being treated with ESWL may not lower the risk of KSD recurrence (I2 = 93.9%, P < 0.001; OR = 1.756, 95% CI = 0.606–5.086, P = 0.299) (Table 2). The P value of Egger’s test was 0.015. After being adjusted with the trim-and-fill method, the pooled data was still not statistically significant (OR = 0.696, 95% CI = 0.265–1.828, P = 0.462). Thus, the pooled result for ESWL was reliable.

24-h urine and serum tests related risk factors

Eleven variables of 24-h urine test including baseline urine volume [26, 30, 42, 48, 50, 54], baseline urine calcium [26, 30, 35, 42, 4850, 54], baseline low urine citrate [26, 30, 35, 42, 4850], baseline urine oxalate [26, 30, 35, 42, 4850], baseline urine sodium [26, 30, 35, 42], baseline urine uric acid [26, 30, 35, 42, 48, 50], baseline urine magnesium [26, 30, 42], baseline urine phosphate [30, 48], baseline urine osmolality [26, 30], CaOx Supersaturation (SS) delta Gibb’s free energy (DG) [30, 49], and 24 h urine test completion [16, 19] were available for data pooling. Besides, two variables, serum tests containing serum calcium [30, 53] and glomerular filtration rate (GFR) [26, 32, 42], were also obtained. Baseline urine was defined as the urine collected when the patient saw a doctor at the first time [54].
After pooling the data of the risk factors mention above, 24 h urine test completion was suggested to be a risk factor for recurrence of KSD (Additional file 2: Figure S3B). Besides, none of them might be risk factors for KSD recurrence (Table 2). No publication bias appeared.

Other risk factors

There were 68 risk factors for recurrence of KSD only reported in only one study. As a reference for future research, we listed them in Fig. 2 to make them more intuitive. Follow-up urine was defined as the urine collected during the follow-up [54].

Subgroup analysis

To reduce the impact of heterogeneity between the studies identified, 30 studies [20, 21, 26, 29, 30, 3335, 38, 42, 43, 45, 46, 48, 50, 51, 5356, 5867] which reported the definition of radiographic KSD relapse were further analyzed (Table 3). The risk factors of higher BMI, personal history of nephrolithiasis, and surgery were still significant.
Table 3
The pooled relationship between various risk factors and any radiographic relapse of kidney stone disease
Risk factors
No. of studies
No. of patients
OR (95% CI)
P value
Model
Heterogeneity
I2 (%)
P
Demographic risk factors
Age
6
5,020
0.996 (0.971–1.022)
0.762
Random
79.5
< 0.001§
BMI
9
15,473
1.062 (1.015–1.111)
0.009#
Random
63.6
0.005#
Sex
12
16,245
1.128 (0.976–1.305)
0.104
Random
56.6
0.008#
Urinary tract anomalies
2
178
1.098 (0.274–4.405)
0.895
Random
65.8
0.087
Kidney stone-related risk factors
Family history of kidney stones
6
1,692
1.089 (0.966–1.227)
0.162
Fixed
0.0
0.830
Personal history of kidney stones
5
2,506
1.402 (1.239–1.587)
< 0.001§
Fixed
0.0
0.426
Diameter of largest kidney stone
4
2,553
1.014 (0.999–1.029)
0.059
Fixed
38.5
0.181
Multiple calculi
4
1,760
1.338 (0.965–1.855)
0.080
Random
80.3
0.002#
Treatment method risk factors
Stone prevention medications
4
2,190
0.674 (0.421–1.079)
0.100
Random
82.6
0.001#
Potassium citrate
3
1733
0.529 (0.221–1.255)
0.148
Random
88.4
< 0.001§
Surgery
2
159
3.178 (1.597–6.322)
0.001#
Fixed
0.0
0.951
ESWl
3
1,120
1.825 (0.386–8.615)
0.448
Random
94.1
< 0.001§
24-h urine and serum tests related risk factors
Baseline urine volume
6
1,789
0.934 (0.756–1.154)
0.528
Random
64.0
0.016*
Baseline urine calcium
7
2,413
1.001 (1.000–1.002)
0.224
Fixed
28.4
0.209
Baseline low urine citrate
6
2,232
1.000 (1.000–1.000)
1.000
Fixed
0.0
0.826
Baseline urine oxalate
6
2,232
0.999 (0.993–1.004)
0.690
Fixed
32.7
0.190
Baseline urine sodium
4
1,719
1.001 (0.999–1.002)
0.325
Fixed
0.0
0.563
Baseline urine uric acid
6
2,232
1.000 (0.999–1.001)
0.992
Fixed
51.4
0.069
Baseline urine magnesium
3
1,095
1.081 (0.777–1.503)
0.645
Fixed
0.0
0.780
Baseline urine phosphate
2
422
0.978 (0.315–3.038)
0.969
Random
89.4
0.002#
Baselin urine osmolality
2
855
1.257 (0.629–2.515)
0.517
Random
83.3
0.014*
Serum calcium
2
348
1.033 (0.787–1.356)
0.817
Fixed
0.0
0.790
GFR
2
1,022
1.505 (0.656–3.453)
0.335
Random
95.9
< 0.001§
BMI, body mass index; OR, odds ratio; CI, confidence intervals; ESWl, extracorporeal shock wave lithotripsy; GFR, glomerular filtration rate
* P < 0.05, # P < 0.01, §P < 0.001

Discussion

This study comprehensively and systematically analyzed the association between various risk factors and the recurrence of KSD. We identified 12 risk factors for predicting the recurrence of KSD. Personal history of nephrolithiasis is vital for identifying the incidence of recurrence. Approximately half of the patients with asymptomatic nephrolithiasis will have symptoms when stones pass during the first stone formation [57]. The 5-year recurrence rate of patients with first-time symptomatic stones is approximately 20% [41]. This rate increases with each additional KSD episode [25].
White race seem to be at a higher risk for KSD than African Americans [68]. Interestingly, our results indicated that Caucasians may undergo more recurrences of KSD than other race patients. It is not exactly known why KSD has a greater recurrence rate in Caucasian, probably because of genetic factors [5]. Thus, clinicians need to take racial differences into account when developing strategies for kidney stone prevention for patients. Younger age may also reflect a genetic component that leads to the early presentation of stones and their recurrence [41].
Family history is associated with a high incidence of KSD, which may also be related to genetic factors. A recent meta-analysis identified 20 nephrolithiasis-associated loci, including CYP24A1, DGKD, DGKH, WDR72, GPIC1, and BCR locus which were predicted to affect vitamin D metabolism and calcium-sensing receptor signaling respectively [69]. Patients with a personal history of KSD, whether symptomatic or asymptomatic, also had an increased risk of recurrence. The recurrence rate increases with each additional kidney stone episode [70]. Furthermore, nonobstructing stones are independent predictors for symptomatic recurrence [41]. If these nonobstructing stones are not treated with surgery, they can pass in the future, become obstructive and then lead to recurrence of symptoms [71].
Obesity, diabetes, hypertension and hyperlipidemia are commonly considered the main clinical characteristics of metabolic syndrome [45]. Metabolic syndrome is related to many kinds of chronic diseases. Epidemiological survey points out that the prevalence of metabolic syndrome is increasing which affects almost a quarter of European population [72]. It is also considered to elevate the rate of nephrolithiasis formation [73]. The KSD patients with higher BMI are easier to experience recurrence in our study as well. A meta-analysis containing 13 cohort studies clarified that relative risk of kidney stones for a 5-unit increment in BMI was 1.21 (1.12–1.30) [74]. In addition, hypertension was also identified as a risk factor for KSD recurrence. This is an important finding because the mechanism of hypertension promoting renal stone formation and recurrence remains unclear. Only a few studies have examined the underlying mechanisms between them. Liu et al,. reported that changes in the blood pressure have a direct consequence on the urinary microbiome and this effect could promote the formation of KSD [75]. Therefore, the control and monitoring of blood pressure is necessary for prevention of KSD recurrence. This is also an important finding of this meta-analysis.
Patients requiring surgery also have a higher risk of KSD recurrence. Common surgical procedures for upper urinary calculi are multitudinous. We believe that compared with the patients receiving conservative treatment, the patients accepting surgery have more complex stone situations, including multiple stones or larger diameter of stone [27]. Pelvic or lower pole stones may contribute to the onset of symptoms in the future, as they may be the stones that have previously detached or formed from residual fragments after surgery [76]. Uric acid stone accounts for about 8% of all stone types [77]. Symptomatic recurrence rate for uric acid at 10 years was approximately 50% which is higher than calcium oxalate and hydroxyapatite stones significantly [78]. These data suggested the importance of stone composition analysis in first-time stone formers.
The American Urologic Association Guidelines and European Association of Urology Guidelines stated that 24-h urine was important for high-risk stone formers [9, 79]. Low volume and high urine concentration are both regarded as risk factors for the formation of nephrolithiasis [80]. Thus, higher fluid intake is recommended in current guidelines, but 24-h urine indexes contribution to our analysis were too weak [9, 79]. Nevertheless, patients who completed a 24-h urine test seemed to have a relatively high KSD recurrence rate. One interpretation is that the patients with more significant KSD are more likely to receive metabolic evaluation including 24-h urine [16]. Considering that the 24-h urine is only a test method, the completion of this test itself should not affect the recurrence of stones. Preventive interventions based on 24-h urine test results do not appear to be working. Considering the evidence for empirical treatment in reducing stone recurrence and the lack of evidence for management based on 24-h urine test outcomes to reduce stone recurrence, Samson et al. suggest that clinicians should consider what results are useful [19]. They questioned whether those providers interpreted 24-h urine test results or counseled patients effectively, or whether patients followed the recommendations.
Potassium citrate is generally considered a relatively safe and commonly used prophylactic for preventing stone recurrence [81]. The treatment of potassium citrate in this study did not seem to reduce the recurrence rate. This This may be related to being affected by the result from Liu et al. [40]. In their research, patients prescribed potassium citrate increased risk of recurrence. They thought that this result might be associated with confounding by indication.
To the knowledge of us, this is the largest and the most comprehensive meta-analysis to explore the risk factors on KSD recurrence. We tried our best to systematically collect and evaluate high quality researches which reported the risk factors for KSD recurrence. This is also the first meta-analysis demonstrate that hypertension, race, 24 h urine test completion, and ureterovesical junction stone are related to KSD recurrence. We are also the first to comprehensively explore the risk factor for radiographic KSD relapse.
There were still some limitations in this study. First, the data of risk factors for recurrence of KSD used in this analysis were reported directly in the articles enrolled. Part of the data were extracted from KM curves. Second, the follow-up times recorded in these enrolled articles were different. Third, only the studies reporting OR, HR or RR were enrolled. Finally, publication bias existed in two risk factors, which could influence our results. The study on this topic is currently very restricted. More well-designed studies exploring the risk factors for relapse of KSD are still required in the future.

Conclusion

12 risk factors including younger age, higher BMI, race of Caucasian, family history of nephrolithiasis, personal history of nephrolithiasis, suspected nephrolithiasis episode prior to first confirmed stone episode, any concurrent asymptomatic (nonobstructing) stone, hypertension, uric acid stone, pelvic or lower pole nephrolithiasis, surgery, and 24 h urine test completion were identified to be associated with relapse of KSD. Additionally, the patients with ureterovesical junction stone might have a lower risk in the relapse of KSD. These results could serve as the risk factors for constructing recurrence prediction models. It also supplied a basis for preventing the recurrence of KSD. Although all conclusions were obtained from results of this analysis directly, several risk factors should be interpreted with caution. More well-designed researches on this topic are needed.

Acknowledgements

None.

Declarations

Not applicable.
Not applicable.
Not applicable.

Competing interests

The authors declare no conflicts of interest concerning this article.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Rukin NJ, Siddiqui ZA, Chedgy ECP, Somani BK. Trends in upper tract stone disease in England: evidence from the hospital episodes statistics database. Urol Int. 2017;98(4):391–6.CrossRefPubMed Rukin NJ, Siddiqui ZA, Chedgy ECP, Somani BK. Trends in upper tract stone disease in England: evidence from the hospital episodes statistics database. Urol Int. 2017;98(4):391–6.CrossRefPubMed
2.
Zurück zum Zitat Chewcharat A, Curhan G. Trends in the prevalence of kidney stones in the United States from 2007 to 2016. Urolithiasis. 2021;49(1):27–39.CrossRefPubMed Chewcharat A, Curhan G. Trends in the prevalence of kidney stones in the United States from 2007 to 2016. Urolithiasis. 2021;49(1):27–39.CrossRefPubMed
3.
Zurück zum Zitat Turk C, Neisius A, Petřík A, Seitz C, Skolarikos A, Thomas K. EAU guidelines on urolithiasis 2020. Edn. presented at the EAU Annual Congress Amsterdam 2020. The European Association of Urology Guidelines Office Place published: Arnhem, The Netherlands. https://uroweb.org/guideline/urolithiasis2020. Turk C, Neisius A, Petřík A, Seitz C, Skolarikos A, Thomas K. EAU guidelines on urolithiasis 2020. Edn. presented at the EAU Annual Congress Amsterdam 2020. The European Association of Urology Guidelines Office Place published: Arnhem, The Netherlands. https://​uroweb.​org/​guideline/​urolithiasis2020​.
4.
Zurück zum Zitat Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med. 1989;111(12):1006–9.CrossRefPubMed Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med. 1989;111(12):1006–9.CrossRefPubMed
6.
Zurück zum Zitat Tasian GE, Kabarriti AE, Kalmus A, Furth SL. Kidney stone recurrence among children and adolescents. J Urol. 2017;197(1):246–52.CrossRefPubMed Tasian GE, Kabarriti AE, Kalmus A, Furth SL. Kidney stone recurrence among children and adolescents. J Urol. 2017;197(1):246–52.CrossRefPubMed
7.
Zurück zum Zitat Daudon M, Jungers P, Bazin D, Williams JC Jr. Recurrence rates of urinary calculi according to stone composition and morphology. Urolithiasis. 2018;46(5):459–70.CrossRefPubMedPubMedCentral Daudon M, Jungers P, Bazin D, Williams JC Jr. Recurrence rates of urinary calculi according to stone composition and morphology. Urolithiasis. 2018;46(5):459–70.CrossRefPubMedPubMedCentral
8.
9.
Zurück zum Zitat Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petřík A, Türk C. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015;67(4):750–63.CrossRefPubMed Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petřík A, Türk C. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015;67(4):750–63.CrossRefPubMed
10.
Zurück zum Zitat Wang Z, Zhang Y, Wei W. Effect of dietary treatment and fluid intake on the prevention of recurrent calcium stones and changes in urine composition: a meta-analysis and systematic review. PLoS ONE. 2021;16(4):e0250257–e0250257.CrossRefPubMedPubMedCentral Wang Z, Zhang Y, Wei W. Effect of dietary treatment and fluid intake on the prevention of recurrent calcium stones and changes in urine composition: a meta-analysis and systematic review. PLoS ONE. 2021;16(4):e0250257–e0250257.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Cheungpasitporn W, Rossetti S, Friend K, Erickson SB, Lieske JC. Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: a systematic review and meta-analysis. J Nephrol. 2016;29(2):211–9.CrossRefPubMed Cheungpasitporn W, Rossetti S, Friend K, Erickson SB, Lieske JC. Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: a systematic review and meta-analysis. J Nephrol. 2016;29(2):211–9.CrossRefPubMed
13.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):e123-130.PubMedPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):e123-130.PubMedPubMedCentral
14.
Zurück zum Zitat Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed
15.
Zurück zum Zitat Wang K, Xu X, Jia G, Jiang H. Risk factors for postpartum stress urinary incontinence: a systematic review and meta-analysis. Reprod Sci. 2020;27(12):2129–45.CrossRefPubMed Wang K, Xu X, Jia G, Jiang H. Risk factors for postpartum stress urinary incontinence: a systematic review and meta-analysis. Reprod Sci. 2020;27(12):2129–45.CrossRefPubMed
16.
Zurück zum Zitat Song S, Thomas IC, Ganesan C, Velaer KN, Chertow GM, Pao AC, Leppert JT. Twenty-four-hour urine testing and urinary stone disease recurrence in veterans. Urology. 2022;159:33–40.CrossRefPubMed Song S, Thomas IC, Ganesan C, Velaer KN, Chertow GM, Pao AC, Leppert JT. Twenty-four-hour urine testing and urinary stone disease recurrence in veterans. Urology. 2022;159:33–40.CrossRefPubMed
17.
Zurück zum Zitat Ito K, Takahashi T, Somiya S, Kanno T, Higashi Y, Yamada H. Predictors of repeat surgery and stone-related events after flexible ureteroscopy for renal stones. Urology. 2021;154:96–102.CrossRefPubMed Ito K, Takahashi T, Somiya S, Kanno T, Higashi Y, Yamada H. Predictors of repeat surgery and stone-related events after flexible ureteroscopy for renal stones. Urology. 2021;154:96–102.CrossRefPubMed
18.
Zurück zum Zitat Iremashvili V, Li S, Dresner SL, Best SL, Hedican SP, Nakada SY. Gender-related differences in the risk factors for repeat stone surgery. Urolithiasis. 2021;49(5):471–6.CrossRefPubMed Iremashvili V, Li S, Dresner SL, Best SL, Hedican SP, Nakada SY. Gender-related differences in the risk factors for repeat stone surgery. Urolithiasis. 2021;49(5):471–6.CrossRefPubMed
19.
Zurück zum Zitat Samson PC, Holt SK, Hsi RS, Sorensen MD, Harper JD. The Association between 24-hour urine and stone recurrence among high risk kidney stone formers: a population level assessment. Urology. 2020;144:71–6.CrossRefPubMed Samson PC, Holt SK, Hsi RS, Sorensen MD, Harper JD. The Association between 24-hour urine and stone recurrence among high risk kidney stone formers: a population level assessment. Urology. 2020;144:71–6.CrossRefPubMed
20.
Zurück zum Zitat Prasanchaimontri P, Monga M. Predictive factors for kidney stone recurrence in type 2 diabetes mellitus. Urology. 2020;143:85–90.CrossRefPubMed Prasanchaimontri P, Monga M. Predictive factors for kidney stone recurrence in type 2 diabetes mellitus. Urology. 2020;143:85–90.CrossRefPubMed
21.
Zurück zum Zitat Nevo A, Levi O, Sidi A, Tsivian A, Baniel J, Margel D, Lifshitz D. Patients treated for uric acid stones reoccur more often and within a shorter interval compared to patients treated for calcium stones. Can Urol Assoc J. 2020;14(11):e555–9.PubMedPubMedCentral Nevo A, Levi O, Sidi A, Tsivian A, Baniel J, Margel D, Lifshitz D. Patients treated for uric acid stones reoccur more often and within a shorter interval compared to patients treated for calcium stones. Can Urol Assoc J. 2020;14(11):e555–9.PubMedPubMedCentral
22.
Zurück zum Zitat Islam AK, Holt S, Reisch J, Nwariaku F, Antonelli J, Maalouf NM. What predicts recurrent kidney stone after parathyroidectomy in patients with primary hyperparathyroidism? J Am Coll Surg. 2020;231(1):74–82.CrossRefPubMed Islam AK, Holt S, Reisch J, Nwariaku F, Antonelli J, Maalouf NM. What predicts recurrent kidney stone after parathyroidectomy in patients with primary hyperparathyroidism? J Am Coll Surg. 2020;231(1):74–82.CrossRefPubMed
23.
Zurück zum Zitat Ingvarsdottir SE, Indridason OS, Palsson R, Edvardsson VO. Stone recurrence among childhood kidney stone formers: results of a nationwide study in Iceland. Urolithiasis. 2020;48(5):409–17.CrossRefPubMed Ingvarsdottir SE, Indridason OS, Palsson R, Edvardsson VO. Stone recurrence among childhood kidney stone formers: results of a nationwide study in Iceland. Urolithiasis. 2020;48(5):409–17.CrossRefPubMed
24.
Zurück zum Zitat Castiglione V, Pottel H, Lieske JC, Lukas P, Cavalier E, Delanaye P, Rule AD. Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones. J Nephrol. 2020;33(1):101–7.CrossRefPubMed Castiglione V, Pottel H, Lieske JC, Lukas P, Cavalier E, Delanaye P, Rule AD. Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones. J Nephrol. 2020;33(1):101–7.CrossRefPubMed
25.
Zurück zum Zitat Vaughan LE, Enders FT, Lieske JC, Pais VM, Rivera ME, Mehta RA, Vrtiska TJ, Rule AD. Predictors of symptomatic kidney stone recurrence after the first and subsequent episodes. Mayo Clin Proc. 2019;94(2):202–10.CrossRefPubMed Vaughan LE, Enders FT, Lieske JC, Pais VM, Rivera ME, Mehta RA, Vrtiska TJ, Rule AD. Predictors of symptomatic kidney stone recurrence after the first and subsequent episodes. Mayo Clin Proc. 2019;94(2):202–10.CrossRefPubMed
26.
Zurück zum Zitat Kang HW, Seo SP, Ha Y-S, Kim WT, Kim Y-J, Yun S-J, Kim W-J, Lee S-C. Twenty-four-hour urine osmolality as a representative index of adequate hydration and a predictor of recurrence in patients with urolithiasis. Int Urol Nephrol. 2019;51(7):1129–35.CrossRefPubMed Kang HW, Seo SP, Ha Y-S, Kim WT, Kim Y-J, Yun S-J, Kim W-J, Lee S-C. Twenty-four-hour urine osmolality as a representative index of adequate hydration and a predictor of recurrence in patients with urolithiasis. Int Urol Nephrol. 2019;51(7):1129–35.CrossRefPubMed
27.
Zurück zum Zitat Iremashvili V, Li S, Penniston KL, Best SL, Hedican SP, Nakada SY. External validation of the recurrence of kidney stone nomogram in a surgical cohort. J Endourol. 2019;33(6):475–9.CrossRefPubMed Iremashvili V, Li S, Penniston KL, Best SL, Hedican SP, Nakada SY. External validation of the recurrence of kidney stone nomogram in a surgical cohort. J Endourol. 2019;33(6):475–9.CrossRefPubMed
28.
Zurück zum Zitat Iremashvili V, Li S, Best SL, Hedican SP, Nakada SY. Clinical and demographic predictors of repeat stone surgery. BJU Int. 2019;124(5):836–41.CrossRefPubMed Iremashvili V, Li S, Best SL, Hedican SP, Nakada SY. Clinical and demographic predictors of repeat stone surgery. BJU Int. 2019;124(5):836–41.CrossRefPubMed
29.
Zurück zum Zitat De Ruysscher C, Pien L, Tailly T, Van Laecke E, Vande Walle J, Prytula A. Risk factors for recurrent urolithiasis in children. J Pediatr Urol. 2019;16:34.e1-34.e9.CrossRef De Ruysscher C, Pien L, Tailly T, Van Laecke E, Vande Walle J, Prytula A. Risk factors for recurrent urolithiasis in children. J Pediatr Urol. 2019;16:34.e1-34.e9.CrossRef
30.
Zurück zum Zitat D’Costa MR, Haley WE, Mara KC, Enders FT, Vrtiska TJ, Pais VM, Jacobsen SJ, McCollough CH, Lieske JC, Rule AD. Symptomatic and radiographic manifestations of kidney stone recurrence and their prediction by risk factors: a prospective cohort study. J Am Soc Nephrol. 2019;30(7):1251–60.CrossRefPubMedPubMedCentral D’Costa MR, Haley WE, Mara KC, Enders FT, Vrtiska TJ, Pais VM, Jacobsen SJ, McCollough CH, Lieske JC, Rule AD. Symptomatic and radiographic manifestations of kidney stone recurrence and their prediction by risk factors: a prospective cohort study. J Am Soc Nephrol. 2019;30(7):1251–60.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Yamashita S, Iguchi T, Nishizawa S, Iba A, Kohjimoto Y, Hara I. Recurrent stone-forming patients have high visceral fat ratio based on computed tomography images compared to first-time stone-forming patients. Int J Urol. 2018;25(6):569–73.CrossRefPubMed Yamashita S, Iguchi T, Nishizawa S, Iba A, Kohjimoto Y, Hara I. Recurrent stone-forming patients have high visceral fat ratio based on computed tomography images compared to first-time stone-forming patients. Int J Urol. 2018;25(6):569–73.CrossRefPubMed
32.
Zurück zum Zitat Wang Q, Liu M, Peng YH, Li L, Lu CY, Zhou T, Gao XF. Correlation between clusterin expression and recurrence of calcium oxalate kidney stone. Acad J Second Mil Univ. 2018;39(3):319–23. Wang Q, Liu M, Peng YH, Li L, Lu CY, Zhou T, Gao XF. Correlation between clusterin expression and recurrence of calcium oxalate kidney stone. Acad J Second Mil Univ. 2018;39(3):319–23.
33.
Zurück zum Zitat Ozgor F, Sahan M, Yanaral F, Savun M, Sarilar O. Flexible ureterorenoscopy is associated with less stone recurrence rates over Shockwave lithotripsy in the management of 10–20 millimeter lower pole renal stone: medium follow-up results. Int Braz J Urol. 2018;44(2):314–22.CrossRefPubMedPubMedCentral Ozgor F, Sahan M, Yanaral F, Savun M, Sarilar O. Flexible ureterorenoscopy is associated with less stone recurrence rates over Shockwave lithotripsy in the management of 10–20 millimeter lower pole renal stone: medium follow-up results. Int Braz J Urol. 2018;44(2):314–22.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Ferraro PM, Ticinesi A, Meschi T, Rodgers A, Di Maio F, Fulignati P, Borghi L, Gambaro G. Short-term changes in urinary relative supersaturation predict recurrence of kidney stones: a tool to guide preventive measures in urolithiasis. J Urol. 2018;200(5):1082–6.CrossRefPubMed Ferraro PM, Ticinesi A, Meschi T, Rodgers A, Di Maio F, Fulignati P, Borghi L, Gambaro G. Short-term changes in urinary relative supersaturation predict recurrence of kidney stones: a tool to guide preventive measures in urolithiasis. J Urol. 2018;200(5):1082–6.CrossRefPubMed
35.
Zurück zum Zitat Kang HW, Seo SP, Kim WT, Kim Y-J, Yun S-J, Kim W-J, Lee S-C. Metabolic characteristics and risks associated with stone recurrence in Korean young adult stone patients. J Endourol. 2017;31(8):806–11.CrossRefPubMed Kang HW, Seo SP, Kim WT, Kim Y-J, Yun S-J, Kim W-J, Lee S-C. Metabolic characteristics and risks associated with stone recurrence in Korean young adult stone patients. J Endourol. 2017;31(8):806–11.CrossRefPubMed
36.
Zurück zum Zitat Shih M-T, Chiang J-H, Liao P-C, Chen H-Y, Chen Y-H, Tang S-H, Wu S-T, Cha T-L, Chen W-C. Association between recurrence of urinary calculi and childbirth: a population-based case–control study. Int Surg. 2016;101(5–6):275–81.CrossRef Shih M-T, Chiang J-H, Liao P-C, Chen H-Y, Chen Y-H, Tang S-H, Wu S-T, Cha T-L, Chen W-C. Association between recurrence of urinary calculi and childbirth: a population-based case–control study. Int Surg. 2016;101(5–6):275–81.CrossRef
37.
Zurück zum Zitat Guerra A, Folesani G, Nouvenne A, Ticinesi A, Allegri F, Pinelli S, Prati B, Morelli I, Guida L, Aloe R, et al. Family history influences clinical course of idiopathic calcium nephrolithiasis: case–control study of a large cohort of Italian patients. J Nephrol. 2016;29(5):645–51.CrossRefPubMed Guerra A, Folesani G, Nouvenne A, Ticinesi A, Allegri F, Pinelli S, Prati B, Morelli I, Guida L, Aloe R, et al. Family history influences clinical course of idiopathic calcium nephrolithiasis: case–control study of a large cohort of Italian patients. J Nephrol. 2016;29(5):645–51.CrossRefPubMed
38.
Zurück zum Zitat El-Assmy A, Harraz AM, Eldemerdash Y, Elkhamesy M, El-Nahas AR, Elshal AM, Sheir KZ. Does lithotripsy increase stone recurrence? A comparative study between extracorporeal shockwave lithotripsy and non-fragmenting percutaneous nephrolithotomy. Arab J Urol. 2016;14(2):108–14.CrossRefPubMedPubMedCentral El-Assmy A, Harraz AM, Eldemerdash Y, Elkhamesy M, El-Nahas AR, Elshal AM, Sheir KZ. Does lithotripsy increase stone recurrence? A comparative study between extracorporeal shockwave lithotripsy and non-fragmenting percutaneous nephrolithotomy. Arab J Urol. 2016;14(2):108–14.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Bos D, Dason S, Matsumoto E, Pinthus J, Allard C. A prospective evaluation of obesometric parameters associated with renal stone recurrence. Can Urol Assoc J. 2016;10(7–8):234–8.CrossRefPubMedPubMedCentral Bos D, Dason S, Matsumoto E, Pinthus J, Allard C. A prospective evaluation of obesometric parameters associated with renal stone recurrence. Can Urol Assoc J. 2016;10(7–8):234–8.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Liu C-C, Hsieh H-M, Wu C-F, Hsieh T-J, Huang S-P, Chou Y-H, Huang C-N, Wu W-J, Wu M-T. Long-term prescription of a-blockers decrease the risk of recurrent urolithiasis needed for surgical intervention—a nationwide population-based study. PLoS ONE. 2015;10(4): e0122494.CrossRefPubMedPubMedCentral Liu C-C, Hsieh H-M, Wu C-F, Hsieh T-J, Huang S-P, Chou Y-H, Huang C-N, Wu W-J, Wu M-T. Long-term prescription of a-blockers decrease the risk of recurrent urolithiasis needed for surgical intervention—a nationwide population-based study. PLoS ONE. 2015;10(4): e0122494.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Rule AD, Lieske JC, Li X, Melton J III, Krambeck AE, Bergstralh EJ. The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol. 2014;25(12):2878–86.CrossRefPubMedPubMedCentral Rule AD, Lieske JC, Li X, Melton J III, Krambeck AE, Bergstralh EJ. The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol. 2014;25(12):2878–86.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Kang HW, Seo SP, Kwon W-A, Woo SH, Kim WT, Kim Y-J, Yun S-J, Lee S-C, Kim W-J. Distinct metabolic characteristics and risk of stone recurrence in patients with multiple stones at the first-time presentation. Urology. 2014;84(2):274–8.CrossRefPubMed Kang HW, Seo SP, Kwon W-A, Woo SH, Kim WT, Kim Y-J, Yun S-J, Lee S-C, Kim W-J. Distinct metabolic characteristics and risk of stone recurrence in patients with multiple stones at the first-time presentation. Urology. 2014;84(2):274–8.CrossRefPubMed
43.
Zurück zum Zitat Kang HW, Seo SP, Kim WT, Kim Y-J, Yun S-J, Lee S-C, Kim W-J. Effect of renal insufficiency on stone recurrence in patients with urolithiasis. J Korean Med Sci. 2014;29(8):1132–7.CrossRefPubMedPubMedCentral Kang HW, Seo SP, Kim WT, Kim Y-J, Yun S-J, Lee S-C, Kim W-J. Effect of renal insufficiency on stone recurrence in patients with urolithiasis. J Korean Med Sci. 2014;29(8):1132–7.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Kruck S, Anastasiadis AG, Herrmann TR, Walcher U, Abdelhafez MF, Nicklas AP, Holzle L, Schilling D, Bedke J, Stenzl A, et al. Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsy. World J Urol. 2013;31(6):1555–61.CrossRefPubMed Kruck S, Anastasiadis AG, Herrmann TR, Walcher U, Abdelhafez MF, Nicklas AP, Holzle L, Schilling D, Bedke J, Stenzl A, et al. Minimally invasive percutaneous nephrolithotomy: an alternative to retrograde intrarenal surgery and shockwave lithotripsy. World J Urol. 2013;31(6):1555–61.CrossRefPubMed
45.
Zurück zum Zitat Kohjimoto Y, Sasaki Y, Iguchi M, Matsumura N, Inagaki T, Hara I. Association of metabolic syndrome traits and severity of kidney stones: results from a nationwide survey on urolithiasis in Japan. Am J Kidney Dis. 2013;61(6):923–9.CrossRefPubMed Kohjimoto Y, Sasaki Y, Iguchi M, Matsumura N, Inagaki T, Hara I. Association of metabolic syndrome traits and severity of kidney stones: results from a nationwide survey on urolithiasis in Japan. Am J Kidney Dis. 2013;61(6):923–9.CrossRefPubMed
46.
Zurück zum Zitat Sorensen MD, Duh Q-Y, Grogan RH, Tran TC, Stoller ML. Differences in metabolic urinary abnormalities in stone forming and nonstone forming patients with primary hyperparathyroidism. Surgery. 2012;151(3):477–83.CrossRefPubMed Sorensen MD, Duh Q-Y, Grogan RH, Tran TC, Stoller ML. Differences in metabolic urinary abnormalities in stone forming and nonstone forming patients with primary hyperparathyroidism. Surgery. 2012;151(3):477–83.CrossRefPubMed
47.
Zurück zum Zitat Pieras E, Ruiz J, Vicens A, Frontera G, Grases F, Piza P. Multivariate analysis of predictive factors in the evolution of renal lithiasis. Actas Urol Esp. 2012;36(6):346–51.CrossRefPubMed Pieras E, Ruiz J, Vicens A, Frontera G, Grases F, Piza P. Multivariate analysis of predictive factors in the evolution of renal lithiasis. Actas Urol Esp. 2012;36(6):346–51.CrossRefPubMed
48.
Zurück zum Zitat Ha Y-S, Tchey D-U, Kang HW, Kim Y-J, Yun S-J, Lee S-C, Kim W-J. Phosphaturia as a promising predictor of recurrent stone formation in patients with urolithiasis. Korean J Urol. 2010;51(1):54–9.CrossRefPubMedPubMedCentral Ha Y-S, Tchey D-U, Kang HW, Kim Y-J, Yun S-J, Lee S-C, Kim W-J. Phosphaturia as a promising predictor of recurrent stone formation in patients with urolithiasis. Korean J Urol. 2010;51(1):54–9.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat DeFoor WR, Jackson E, Minevich E, Caillat A, Reddy P, Sheldon C, Asplin J. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate. Urology. 2010;76(1):242–5.CrossRefPubMed DeFoor WR, Jackson E, Minevich E, Caillat A, Reddy P, Sheldon C, Asplin J. The risk of recurrent urolithiasis in children is dependent on urinary calcium and citrate. Urology. 2010;76(1):242–5.CrossRefPubMed
50.
Zurück zum Zitat Kim YJ, Kim TH, Yun SJ, Kim ME, Kim WJ, Lee SC. Renal phosphate control as a reliable predictive factor of stone recurrence. J Urol. 2009;181(6):2566–72 (discussion 2572).CrossRefPubMed Kim YJ, Kim TH, Yun SJ, Kim ME, Kim WJ, Lee SC. Renal phosphate control as a reliable predictive factor of stone recurrence. J Urol. 2009;181(6):2566–72 (discussion 2572).CrossRefPubMed
51.
Zurück zum Zitat Lee S-C, Kim Y-J, Kim T-H, Yun S-J, Lee NK, Kim W-J. Impact of obesity in patients with urolithiasis and its prognostic usefulness in stone recurrence. J Urol. 2008;179(2):570–4.CrossRefPubMed Lee S-C, Kim Y-J, Kim T-H, Yun S-J, Lee NK, Kim W-J. Impact of obesity in patients with urolithiasis and its prognostic usefulness in stone recurrence. J Urol. 2008;179(2):570–4.CrossRefPubMed
52.
Zurück zum Zitat Krambeck AE, LeRoy AJ, Patterson DE, Gettman MT. Long-term outcomes of percutaneous nephrolithotomy compared to shock wave lithotripsy and conservative management. J Urol. 2008;179(6):2233–7.CrossRefPubMed Krambeck AE, LeRoy AJ, Patterson DE, Gettman MT. Long-term outcomes of percutaneous nephrolithotomy compared to shock wave lithotripsy and conservative management. J Urol. 2008;179(6):2233–7.CrossRefPubMed
53.
Zurück zum Zitat Unal D, Yeni E, Verit A, Karatas OF. Prognostic factors effecting on recurrence of urinary stone disease: a multivariate analysis of everyday patient parameters. Int Urol Nephrol. 2005;37(3):447–52.CrossRefPubMed Unal D, Yeni E, Verit A, Karatas OF. Prognostic factors effecting on recurrence of urinary stone disease: a multivariate analysis of everyday patient parameters. Int Urol Nephrol. 2005;37(3):447–52.CrossRefPubMed
54.
Zurück zum Zitat Daudon M, Hennequin C, Boujelben G, Lacour B, Jungers P. Serial crystalluria determination and the risk of recurrence in calcium stone formers. Kidney Int. 2005;67(5):1934–43.CrossRefPubMed Daudon M, Hennequin C, Boujelben G, Lacour B, Jungers P. Serial crystalluria determination and the risk of recurrence in calcium stone formers. Kidney Int. 2005;67(5):1934–43.CrossRefPubMed
55.
Zurück zum Zitat Abe T, Akakura K, Kawaguchi M, Ueda T, Ichikawa T, Ito H, Nozumi K, Suzuki K. Outcomes of shockwave lithotripsy for upper urinary-tract stones: a large-scale study at a single institution. J Endourol. 2005;19(7):768–73.CrossRefPubMed Abe T, Akakura K, Kawaguchi M, Ueda T, Ichikawa T, Ito H, Nozumi K, Suzuki K. Outcomes of shockwave lithotripsy for upper urinary-tract stones: a large-scale study at a single institution. J Endourol. 2005;19(7):768–73.CrossRefPubMed
56.
Zurück zum Zitat Parks JH, Worcester EM, Coe FL, Evan AP, Lingeman JE. Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int. 2004;66(2):777–85.CrossRefPubMed Parks JH, Worcester EM, Coe FL, Evan AP, Lingeman JE. Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int. 2004;66(2):777–85.CrossRefPubMed
57.
Zurück zum Zitat Mardis HK, Parks JH, Muller G, Ganzel K, Coe FL. Outcome of metabolic evaluation and medical treatment for calcium nephrolithiasis in a private urological practice. J Urol. 2004;171(1):85–8.CrossRefPubMed Mardis HK, Parks JH, Muller G, Ganzel K, Coe FL. Outcome of metabolic evaluation and medical treatment for calcium nephrolithiasis in a private urological practice. J Urol. 2004;171(1):85–8.CrossRefPubMed
58.
Zurück zum Zitat Afshar K, McLorie G, Papanikolaou F, Malek R, Harvey E, Pippi-Salle JL, Bagli DJ, Khoury AE, Farhat W. Outcome of small residual stone fragments following shock wave lithotripsy in children. J Urol. 2004;172(4):1600–3.CrossRefPubMed Afshar K, McLorie G, Papanikolaou F, Malek R, Harvey E, Pippi-Salle JL, Bagli DJ, Khoury AE, Farhat W. Outcome of small residual stone fragments following shock wave lithotripsy in children. J Urol. 2004;172(4):1600–3.CrossRefPubMed
59.
Zurück zum Zitat Siener R, Glatz S, Nicolay C, Hesse A. Prospective study on the efficacy of a selective treatment and risk factors for relapse in recurrent calcium oxalate stone patients. Eur Urol. 2003;44(4):467–74.CrossRefPubMed Siener R, Glatz S, Nicolay C, Hesse A. Prospective study on the efficacy of a selective treatment and risk factors for relapse in recurrent calcium oxalate stone patients. Eur Urol. 2003;44(4):467–74.CrossRefPubMed
60.
Zurück zum Zitat Chen YY, DeVivo MJ, Stover SL, Lloyd LK. Recurrent kidney stone: a 25-year follow-up study in persons with spinal cord injury. Urology. 2002;60(2):228–32.CrossRefPubMed Chen YY, DeVivo MJ, Stover SL, Lloyd LK. Recurrent kidney stone: a 25-year follow-up study in persons with spinal cord injury. Urology. 2002;60(2):228–32.CrossRefPubMed
61.
Zurück zum Zitat Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, Novarini A. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 2002;346(2):77–84.CrossRefPubMed Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, Novarini A. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 2002;346(2):77–84.CrossRefPubMed
62.
Zurück zum Zitat Jendie-Bengten C, Tiselius HG. Long-term follow-up of stone formers treated with a low dose of sodium potassium citrate. Scand J Urol Nephrol. 2000;34(1):36–41.CrossRef Jendie-Bengten C, Tiselius HG. Long-term follow-up of stone formers treated with a low dose of sodium potassium citrate. Scand J Urol Nephrol. 2000;34(1):36–41.CrossRef
63.
Zurück zum Zitat Trinchieri A, Ostini F, Nespoli R, Rovera F, Montanari E, Zanetti G. A prospective study of recurrence rate and risk factors for recurrence after a first renal stone. J Urol. 1999;162(1):27–30.CrossRefPubMed Trinchieri A, Ostini F, Nespoli R, Rovera F, Montanari E, Zanetti G. A prospective study of recurrence rate and risk factors for recurrence after a first renal stone. J Urol. 1999;162(1):27–30.CrossRefPubMed
64.
Zurück zum Zitat Ettinger B, Pak CYC, Citron JT, Thomas C, AdamsHuet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 1997;158(6):2069–73.CrossRefPubMed Ettinger B, Pak CYC, Citron JT, Thomas C, AdamsHuet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 1997;158(6):2069–73.CrossRefPubMed
65.
Zurück zum Zitat Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol. 1996;144(1):25–33.CrossRefPubMed Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol. 1996;144(1):25–33.CrossRefPubMed
66.
Zurück zum Zitat Gambaro G, Marchini F, Piccoli A, Nassuato MA, Bilora F, Baggio B. The abnormal red-cell oxalate transport is a risk factor for idiopathic calcium nephrolithiasis: a prospective study. J Am Soc Nephrol. 1996;7(4):608–12.CrossRefPubMed Gambaro G, Marchini F, Piccoli A, Nassuato MA, Bilora F, Baggio B. The abnormal red-cell oxalate transport is a risk factor for idiopathic calcium nephrolithiasis: a prospective study. J Am Soc Nephrol. 1996;7(4):608–12.CrossRefPubMed
67.
Zurück zum Zitat Streem SB. Long-term incidence and risk factors for recurrent stones following percutaneous nephrostolithotomy or percutaneous nephrostolithotomy/extracorporeal shock wave lithotripsy for infection related calculi. J Urol. 1995;153(3 Pt 1):584–7.CrossRefPubMed Streem SB. Long-term incidence and risk factors for recurrent stones following percutaneous nephrostolithotomy or percutaneous nephrostolithotomy/extracorporeal shock wave lithotripsy for infection related calculi. J Urol. 1995;153(3 Pt 1):584–7.CrossRefPubMed
68.
Zurück zum Zitat Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int. 2003;63(5):1817–23.CrossRefPubMed Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int. 2003;63(5):1817–23.CrossRefPubMed
69.
Zurück zum Zitat Howles SA, Wiberg A, Goldsworthy M, Bayliss AL, Gluck AK, Ng M, Grout E, Tanikawa C, Kamatani Y, Terao C, et al. Genetic variants of calcium and vitamin D metabolism in kidney stone disease. Nat Commun. 2019;10(1):5175–5175.CrossRefPubMedPubMedCentral Howles SA, Wiberg A, Goldsworthy M, Bayliss AL, Gluck AK, Ng M, Grout E, Tanikawa C, Kamatani Y, Terao C, et al. Genetic variants of calcium and vitamin D metabolism in kidney stone disease. Nat Commun. 2019;10(1):5175–5175.CrossRefPubMedPubMedCentral
70.
Zurück zum Zitat Thongprayoon C, Krambeck AE, Rule AD. Determining the true burden of kidney stone disease. Nat Rev Nephrol. 2020;16(12):736–46.CrossRefPubMed Thongprayoon C, Krambeck AE, Rule AD. Determining the true burden of kidney stone disease. Nat Rev Nephrol. 2020;16(12):736–46.CrossRefPubMed
71.
Zurück zum Zitat Glowacki LS, Beecroft ML, Cook RJ, Pahl D, Churchill DN. The natural history of asymptomatic urolithiasis. J Urol. 1992;147(2):319–21.CrossRefPubMed Glowacki LS, Beecroft ML, Cook RJ, Pahl D, Churchill DN. The natural history of asymptomatic urolithiasis. J Urol. 1992;147(2):319–21.CrossRefPubMed
72.
Zurück zum Zitat Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Mañas LR, Mattace Raso FU, Muiesan ML, Ryliškytė L, Rietzschel E, et al. Metabolic syndrome across Europe: different clusters of risk factors. Eur J Prev Cardiol. 2015;22(4):486–91.CrossRefPubMed Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Mañas LR, Mattace Raso FU, Muiesan ML, Ryliškytė L, Rietzschel E, et al. Metabolic syndrome across Europe: different clusters of risk factors. Eur J Prev Cardiol. 2015;22(4):486–91.CrossRefPubMed
73.
Zurück zum Zitat Chang C-W, Ke H-L, Lee J-I, Lee Y-C, Jhan J-H, Wang H-S, Shen J-T, Tsao Y-H, Huang S-P, Geng J-H. Metabolic syndrome increases the risk of kidney stone disease: a cross-sectional and longitudinal cohort study. Journal of personalized medicine. 2021;11(11):1154.CrossRefPubMedPubMedCentral Chang C-W, Ke H-L, Lee J-I, Lee Y-C, Jhan J-H, Wang H-S, Shen J-T, Tsao Y-H, Huang S-P, Geng J-H. Metabolic syndrome increases the risk of kidney stone disease: a cross-sectional and longitudinal cohort study. Journal of personalized medicine. 2021;11(11):1154.CrossRefPubMedPubMedCentral
74.
Zurück zum Zitat Aune D, Mahamat-Saleh Y, Norat T, Riboli E. Body fatness, diabetes, physical activity and risk of kidney stones: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2018;33(11):1033–47.CrossRefPubMedPubMedCentral Aune D, Mahamat-Saleh Y, Norat T, Riboli E. Body fatness, diabetes, physical activity and risk of kidney stones: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2018;33(11):1033–47.CrossRefPubMedPubMedCentral
75.
Zurück zum Zitat Liu F, Zhang N, Jiang P, Zhai Q, Li C, Yu D, Wu Y, Zhang Y, Lv L, Xu X, et al. Characteristics of the urinary microbiome in kidney stone patients with hypertension. J Transl Med. 2020;18(1):130.CrossRefPubMedPubMedCentral Liu F, Zhang N, Jiang P, Zhai Q, Li C, Yu D, Wu Y, Zhang Y, Lv L, Xu X, et al. Characteristics of the urinary microbiome in kidney stone patients with hypertension. J Transl Med. 2020;18(1):130.CrossRefPubMedPubMedCentral
76.
Zurück zum Zitat Selby MG, Vrtiska TJ, Krambeck AE, McCollough CH, Elsherbiny HE, Bergstralh EJ, Lieske JC, Rule AD. Quantification of asymptomatic kidney stone burden by computed tomography for predicting future symptomatic stone events. Urology. 2015;85(1):45–50.CrossRefPubMed Selby MG, Vrtiska TJ, Krambeck AE, McCollough CH, Elsherbiny HE, Bergstralh EJ, Lieske JC, Rule AD. Quantification of asymptomatic kidney stone burden by computed tomography for predicting future symptomatic stone events. Urology. 2015;85(1):45–50.CrossRefPubMed
77.
Zurück zum Zitat Lieske JC, Rule AD, Krambeck AE, Williams JC, Bergstralh EJ, Mehta RA, Moyer TP. Stone composition as a function of age and sex. Clin J Am Soc Nephrol. 2014;9(12):2141–6.CrossRefPubMedPubMedCentral Lieske JC, Rule AD, Krambeck AE, Williams JC, Bergstralh EJ, Mehta RA, Moyer TP. Stone composition as a function of age and sex. Clin J Am Soc Nephrol. 2014;9(12):2141–6.CrossRefPubMedPubMedCentral
78.
Zurück zum Zitat Singh P, Enders FT, Vaughan LE, Bergstralh EJ, Knoedler JJ, Krambeck AE, Lieske JC, Rule AD. Stone composition among first-time symptomatic kidney stone formers in the community. Mayo Clin Proc. 2015;90(10):1356–65.CrossRefPubMed Singh P, Enders FT, Vaughan LE, Bergstralh EJ, Knoedler JJ, Krambeck AE, Lieske JC, Rule AD. Stone composition among first-time symptomatic kidney stone formers in the community. Mayo Clin Proc. 2015;90(10):1356–65.CrossRefPubMed
79.
Zurück zum Zitat Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316–24.CrossRefPubMed Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, et al. Medical management of kidney stones: AUA guideline. J Urol. 2014;192(2):316–24.CrossRefPubMed
80.
Zurück zum Zitat Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, Knoll T. EAU guidelines on interventional treatment for urolithiasis. Eur Urol. 2016;69(3):475–82.CrossRefPubMed Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, Knoll T. EAU guidelines on interventional treatment for urolithiasis. Eur Urol. 2016;69(3):475–82.CrossRefPubMed
81.
Zurück zum Zitat Moe OW, Pearle MS, Sakhaee K. Pharmacotherapy of urolithiasis: evidence from clinical trials. Kidney Int. 2011;79(4):385–92.CrossRefPubMed Moe OW, Pearle MS, Sakhaee K. Pharmacotherapy of urolithiasis: evidence from clinical trials. Kidney Int. 2011;79(4):385–92.CrossRefPubMed
Metadaten
Titel
Risk factors for kidney stone disease recurrence: a comprehensive meta-analysis
verfasst von
Kai Wang
Jing Ge
Wenlong Han
Dong Wang
Yinjuan Zhao
Yanhao Shen
Jiexun Chen
Dongming Chen
Jing Wu
Ning Shen
Shuai Zhu
Bin Xue
Xianlin Xu
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
BMC Urology / Ausgabe 1/2022
Elektronische ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-022-01017-4

Weitere Artikel der Ausgabe 1/2022

BMC Urology 1/2022 Zur Ausgabe

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.